8月17日，昭衍新药(06127)盘中上涨6.22%，报26.64港元，成交额4471.66万港元。
消息面上，公司近日在投资者互动平台披露，截至一季度末在手订单金额为31亿元人民币，前期存量低价订单正在有序出清，非人灵长类实验动物价格和订单签约价格相较前期均有所回升。同时，CXO板块整体走强，机构研报指出行业景气度上行信号明确，全球生物医药投融资回暖带动研发需求复苏，板块内金斯瑞生物科技涨5.23%、药明生物涨4.12%、药明康德涨3.95%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.